The aim of this study is to investigate additional genetic alterations in papillary thyroid carcinomas (PTCs) with known RET/PTC rearrangements. We applied arraybased comparative genomic hybridization (array CGH) to 33 PTC (20 PTC from adults, 13 post-Chernobyl PTC from children) with known RET/PTC status. Principal component analysis and hierarchical cluster analysis identified cases with similar aberration patterns. Significant deviations between tumour-groups were obtained by statistical testing (Fisher's exact test in combination with Benjamini-Hochberg FDR-controlling procedure). FISH analysis on FFPE sections was applied to validate the array CGH data. Deletions were found more frequently in RET/PTC-positive and RET/PTC-negative tumours than amplifications. Specific aberration signatures were identified that discriminated between RET/PTC-positive and RET/PTC-negative cases (aberrations on chromosomes 1p, 3q, 4p, 7p, 9p/q, 10q, 12q, 13q and 21q). In addition, childhood and adult RET/PTC-positive cases differ significantly for a deletion on the distal part of chromosome 1p. There are additional alterations in RET/PTC-positive tumours, which may act as modifiers of RET activation. In contrast, alterations in RET/ PTC-negative tumours indicate alternative routes of tumour development. The data presented serve as a starting point for further studies on gene expression and function of genes identified in this study.
Introduction
A frequent genetic alteration in papillary thyroid carcinomas (PTCs) is rearrangement of the RET proto-oncogene, which has been assigned to chromosomal band 10q11.2 (Grieco et al., 1990; Pierotti et al., 1992) . RET/PTC oncogenic activation is the result of chromosomal rearrangements, which fuse the RET tyrosine kinase (RET-TK) domain to the 5 0 -terminal region of heterologous genes. The rearrangements are a marker for PTCs as their very name RET/PTC implies. At least 16 chimeric mRNAs involving 11 different genes have been reported (reviewed in Santoro et al., 2004) of which RET/PTC1 (RET rearrangement with H4) and RET/PTC3 (RET rearrangement with RFG/ ELE1) are by far the most common . The incidence of RET/PTC in radiation-induced childhood PTCs is in the range of 50-70% (Klugbauer et al., 1995; Smida et al., 1999; Thomas et al., 1999; Rabes et al., 2000) , whereas in sporadic papillary carcinomas in adults the incidence is somewhat lower (5-30%) (Jhiang and Mazzaferri, 1994) . However, the identification of RET/PTC in other common thyroid tumour histotypes such as oncocytic adenomas and carcinomas (Cheung et al., 2000) , and even in hyperplastic thyroid nodules (Ishizaka et al., 1991; Elisei et al., 2001 ) and Hashimoto's thyroiditis (Rhoden et al., 2006) , seems to challenge the validity of RET/PTC as a tumour marker and its specificity for PTC. Moreover, it has been recently shown that the level of RET/PTC expression in papillary carcinoma is highly variable, suggesting that the distribution of RET/PTC within one tumour may not be homogenous (Rhoden et al., 2004; Unger et al., 2004) . This is also supported by recent fluorescence in situ hybridization (FISH) studies by ourselves and others (Unger et al., 2004; Ciampi and Nikiforov, 2007) .
To investigate whether other genes are involved in thyroid carcinogenesis, we have studied a series of PTCs by array-based comparative genomic hybridization (array CGH). Array CGH represents an approach using mapped sequences arrayed onto glass slides instead of metaphase chromosomes that are used in conventional CGH as hybridization targets. This generates a higher resolution dependent on the insert size and density of the mapped sequences. In this study, we used bacterial artificial chromosome (BAC)-arrays (B3400 clones) that allow the examination of the entire genome for chromosomal copy number changes (DNA gains and losses) with a resolution of 1 Mb. A striking advantage of this technology is its use on archival paraffinembedded material (van Beers et al., 2006) .
In this study on PTC, array CGH was used to investigate chromosomal changes in 33 papillary thyroid post-Chernobyl adult and childhood PTC. In all cases, the tumours have been pre-characterized in terms of RET/PTC rearrangements.
The aim of this study was to determine differences in chromosomal aberration patterns between RET/PTCpositive and -negative PTC. The identification of characteristic alteration signatures in different tumour groups (adult, childhood, RET/PTC-positive, RET/PTC-negative) enabled a subsequent characterization of candidate genes that may either cooperate with or substitute for RET/PTC in papillary thyroid carcinogenesis.
Results
We analysed 33 post-Chernobyl PTCs from adults and children for chromosomal changes by array CGH. The tumours were also characterized for the presence of RET/ PTC rearrangements on a single-cell level by FISH. The RET/PTC status of each tumour and the patient's demographic and clinical data are summarized in Table 1 .
Chromosomal imbalances, hierarchical cluster analysis and principal component analysis In general, DNA losses occurred more frequently than DNA gains. The most frequent imbalances (in more than 30% of tumours) were losses on chromosomes 1, 6, 7, 9, 10, 11, 12, 13, 16, 19, 20, 22 and gains on chromosomes 10, 12, 19, 20, 21 (Figure 1 ). Hierarchical cluster analysis (HCA) employing the correlations between the array CGH profiles segregated significantly nine adult RET/PTC-negative cases from all other cases (Fisher's exact test, Po0.05; Figure 2 ). The patterns of array CGH differences observed using HCA were confirmed using principal component analysis 
Comparison of tumour groups
On the basis of the results from the cluster analysis, we grouped tumours into RET/PTC-positive from adults, RET/PTC-positive from children and RET/PTCnegative tumours from adults and analysed them for significant differences. Chromosomal imbalances arranged by each tumour group are visualized by frequency plots (Figure 3 ). As deviations between these frequency plots were visible, each BAC clone was examined for the difference between two tumour groups by the Fisher's exact test. Significant test results (adjusted P-value o0.05) were obtained for adult RET/PTC-positive versus adult RET/PTC-negative cases (1253 BAC clones were tested, 441 were significant on different chromosomes) and for adult RET/PTCpositive versus childhood RET/PTC-positive cases (1239 BAC clones were tested, 34 were significant, all on chromosome 1p35.3-36.31). Significant differences are summarized in Table 2 . The majority of these aberrations are specific for RET/PTC-positive cases. Characteristic aberration signatures became apparent discriminating between RET/PTC-positive and RET/ PTC-negative cases (aberrations on chromosome 1p, 3q, 4p, 7p, 9p/q, 10q, 12q, 13q and 21q). In addition, childhood and adult RET/PTC-positive cases differ significantly for a deletion on the distal part of chromosome 1p.
FISH analysis and candidate genes
Amplified and deleted regions from array CGH analysis were confirmed by FISH on formalin-fixed and paraffinembedded (FFPE) sections using digoxigenin or biotinlabelled BAC clones ( Figure 4 ). All chromosomal imbalances with exception of deletion 1q31 in cases 27 and 28 and deletion 1p22 in case 28 were validated. The frequency of aberrant FISH signals in each case investigated is given in Table 3 . For chromosomal regions that showed significant differences in two tumour groups or consistency in all tumour groups, candidate genes have been selected from the Ensembl database (www.ensembl.org). Specific candidates that have been reported to be related to tumour growth and development are highlighted in Tables 4 and 5 .
Examples of an altered consensus region on 1p36.31-35.3 (deletion), 7q21.3-22.1 (deletion) and 12q24.23-24.31 (amplification) as well as confirmatory FISH analyses on a FFPE sections are shown in Figure 4 .
Involvement of candidate genes in molecular pathways
We identified 31 cancer-related candidate genes. For the retrieval of pathways linking these candidate genes, we used the web-accessible Pathway Interaction Database (National Cancer Institute, http://www.pid.nci.nih.giv). This database search revealed a subset of candidate genes (Jak1, Jak2, Tnf, Pten, Foxo1A, Rb1 and Tiam1) that exhibit molecular interactions and could be linked to the apoptosis, interleukin-27, angiopoietin receptor and the phosphatidyl-inositol 3-kinase (PI3K)/mitogenactivated protein (MAP) kinase pathways. 
Discussion
We describe distinct chromosomal changes in PTCs identified by array CGH. To our knowledge, this represents the first array CGH study on PTCs, which includes post-Chernobyl thyroid tumours. We report Finn et al., 2004; Richter et al., 2004) . The similarity in the results from conventional and array CGH demonstrates the reliability of the array CGH approach we used. In addition, we have also validated our array CGH findings for specific chromosomal regions (Tables 3 and 4) by FISH on FFPE sections. In the majority of cases, matching results could be observed by array CGH and FISH. The PTC cohort investigated in this study consists of sporadic adult and post-Chernobyl tumours, and is characterized by a high frequency of RET/PTC rearrangements and only three sporadic adult cases with BRAF T1796A mutations. This is a surprising finding in sporadic adult PTC because, on the basis of literature, these tumours are expected to exhibit a higher BRAF mutation rate and a lower RET/PTC frequency (Ciampi and Nikiforov, 2007) . This contradicting result can be Co-hybridization with clone RP11-328M22 (7q31) for reference. (Ciampi and Nikiforov, 2007) . We specifically chose a cohort with such features to generate data with a homogeneous genetic background, while a mixture of cases with RET/PTC and BRAF mutations would have weakened the statistical power in terms of grouping, especially the RET/PTC-negative cases together. Our array CGH data and following cluster analysis clearly show a discrimination of nine cases from all other cases and, thus, reflects a different genomic aberration pattern in PTC from adults without RET/PTC rearrangement in comparison to PTC with RET/PTC rearrangements. This finding led us to separate our PTC cases according to their RET/PTC status and age. It is of note that a statistical comparison of RET/PTC-positive cases from adults, RET/PTCpositive cases from children aged under 16 years at operation and RET/PTC-negative cases from adults revealed specific aberration signatures for particular tumour groups (Table 2) , while sharing other deletions/ gains in chromosomal regions. We have clearly demonstrated that RET/PTC-positive and RET/PTC-negative PTC show different chromosomal aberration patterns.
Losses on chromosome 1p35-36 discriminated between adult and childhood RET/PTC-positive PTC, whereas losses on chromosome 7 appear to be specific for adult RET/PTC-negative cases, and aberrations on chromosome 1p, 3q, 4p, 7p, 9p/q, 10q, 12q, 13q and 21q differentiate between adult and childhood PTCs. The detailed list of characteristic aberrations in RET/PTCpositive and RET/PTC-negative PTCs (Table 2) provided a starting point for mining candidate genes from databases in altered regions that are located within the BAC clones from the array. This analysis revealed 31 candidate genes that have already been reported to be related to tumour growth and development (Table 4 ). In addition to these specific classifiers in PTC, which are dependent on RET/PTC status and age, we identified 15 tumour-related candidate genes ( Table 5 ) that occur consistently in each tumour and independently of these parameters. It is of note that 21 tumour-suppressor genes map within either the specific or the consistently altered regions. TIMP3 and PTEN have already been reported as tumour suppressors in thyroid tumours (Hu et al., 2006; Hou et al., 2007; Wang et al., 2007) , while others are involved in a variety of different tumour types, for example, TGFBR3 and ANXA7 in prostate cancer (Torosyan et al., 2006; Dong et al., 2007) , TNFSF15 and TUSC1 in lung cancer (Shan et al., 2004; Hou et al., 2005) , SYK and Net1 in breast cancer (Repana et al., 2006; Huang et al., 2007) , SLIT1, RSU1 and KLF6 in gliomas and glioblastosmas (Chunduru et al., 2002; Dickinson et al., 2004; Camacho-Vanegas et al., 2007) , DBC1 in bladder cancer (Louhelainen et al., 2006) , DEC1 in oesophageal squamous cell carcinomas (Yang et al., 2005) , RB1 in retinoblastoma (Corson and Gallie, 2007) and LATS2 and DLEU7 in leukaemias (Hammarsund et al., 2004; Jimenez-Velasco et al., 2005) . Some of these tumour suppressors have influence on the regulation of chromatin acetylation 
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Another interesting gene affected by a deletion is FANCC, which is known to be downregulated in head and neck cancers (Wreesmann et al., 2007) and is part of the Fanconi's anaemia/BRCA pathway, which is frequently disrupted in tumours with poor prognosis. Two genes of the apoptosis pathway, TNFRSF25 and CASP9, are located within the deleted region on 1p35.3-36.31, which is specific for RET/PTC-positive cases from adults. TNFRSF25 is also a candidate tumour suppressor in neuroblastomas (Okawa et al., 2008) , whereas CASP9 deregulation has frequently been described in human cancers, for example in gastric carcinomas where it is reported that its activation is inhibited by phosphorylation through the MAP kinase pathway (Yoo et al., 2007) . An interesting finding of this study is the deletion of RET because its activated form, RET/PTC, is known as a marker of PTC. This apparent contradiction, being simultaneously present as an activated oncogene and affected by a deletion, can be explained by a distinct genetic heterogeneity in tumour tissues as already extensively reported for RET/PTC (Unger et al., 2004 Ciampi and Nikiforov, 2007) . We confirmed this genetic heterogeneity for RET/PTC by performing RET/PTC analysis at a single-cell level by FISH in this study (data not shown). Thus, it appears that within one tumour, RET/PTC is present in a subgroup of tumour cells, while RET is obviously deleted in another tumour cell population. Interestingly, a distinct heterogeneous distribution of gene alterations within a tumour became apparent also for deletions and amplifications confirmed by FISH with BAC clones for selected regions (Figure 4 ) and by array CGH analysis of three microdissected areas of RET/PTC-positive tumour case no. 3. From the latter experiment it became obvious that some alterations are recurrent in each area and, thus, visible in the whole tumour profile, but in contrast, numerous imbalances are present only in subgroups of tumour cells. This is also the case for deletions on chromosome 10 involving the RET locus, which appeared deleted in two microdissected areas, but not deleted in another area resulting in a profile for the whole tumour where chromosome 10 deletion is only marginally visible. To define molecular pathways involving the identified candidate genes, we used the web-accessible Pathway Interaction Database. It turned out that the apoptosis, interleukin-27, angiopoietin receptor and the PI3K/ MAP kinase pathways are related to these candidate genes. The well-known tumour-suppressor gene, RB1, which was deleted in the RET/PTC-positive group of tumours and which is a key gene in the FAS signalling pathway (Nagata, 1994 ) is linked to the caspase cascade in the apoptosis pathway by CASP3 (Riedl and Salvesen, 2007) . In normal cells an activation of RB1 by CASP3 leads to a repressed transcription of a series of cell cycle proteins by recruiting methyl-transferases that subsequently induce transcription-inactive heterochromatin (Tan and Wang, 1998; Nielsen et al., 2001) . A lack of this process RB1-deleted tumour cells may lead to increased genomic instability and tumour progression.
The protein tumour necrosis factor-a, which is upstream of the caspase cascade of the apoptosis pathway and which appeared deleted in the RET/ PTC-positive tumour group, connects this pathway to the interleukin-27-mediated pathway (JAK1/2, tyrosine kinase, deleted in the RET/PTC-positive tumour group), to the angiopoietin receptor pathway (FOXO1A, transcription factor, deleted in the RET/PTC-positive tumour group) and to the PI3K pathway. The latter pathway is also related to TIAM1, which is amplified in the RET/PTC-positive tumour group. A central protein of this pathway, RAC, is usually activated by TIAM1 or by PI3K (Collard et al., 1996; Worthylake et al., 2000; Djeu et al., 2002) and acts as a negative regulator. Another protein with the same function in the PI3K pathway is the tumour supressor gene PTEN (Li and Ross, 2007) , which was found to be deleted in the RET/PTC-positive tumours of our study.
In conclusion, our findings indicate that different routes of tumour development in PTC are likely to exist. There are additional alterations in RET/PTC-positive tumours, which may act as modifiers of RET activation. This is supported by the finding that the MAP kinase pathway appeared to be linked to a network of pathways of which the apoptosis and the PI3K pathways are most prominent. The involvement of different pathways is also in line with the finding of genetic heterogeneity within PTC from this and previous studies. Different characteristic alterations in RET/ PTC-negative tumours indicate alternative paths of tumour development. These would appear to be different from aberrations that may relate to BRAF mutation, as we were unable to detect BRAF mutation in a significant number of sporadic tumours using a previously validated technique (Powell et al., 2005) . The data presented here may serve as a starting point for further expression and functional studies of the reported candidate genes and point to a very complex nature of genetic alterations in PTC.
Materials and methods
Patient data, treatment and tumour tissues Tumour samples were collected from 33 patients with PTC. Twenty of these were adults at the time of clinical presentation (16 female, 4 male) and were operated at the Thyroid Tumour Centre in Minsk, Belarus. In addition, 13 childhood patients (eight female, five male) with histologically verified PTCs, developed in the aftermath of the Chernobyl reactor accident, were obtained from the Institute of Endocrinology and Metabolism in Kiev, Ukraine. Appropriate informed consent was obtained from the patients or their guardians. The study was approved by the Ethics Committee of the Bavarian General Medical Council. All tumours were diagnosed as papillary carcinomas, according to the WHO classification of thyroid tumours (DeLellis et al., 2004) and further subdivided according to their dominant histological architecture (papillary, follicular, solid). All childhood PTC cases showed a dominantly solid phenotype. Patient data are summarized in Table 1 . A tissue section adjacent to that used for DNA extraction was stained with haematoxylin and eosin, and the presence of tumour epithelium was verified. Slides for DNA extraction and subsequent FISH studies were obtained by microdissection of areas of normal tissue from the slide, resulting in tumour cell enrichment. Either FFPE sections or frozen tissue sections were used for DNA isolation for array CGH. FISH experiments were performed on FFPE sections.
Intratumour heterogeneity of RET/PTC-positive case no. 3 From PTC case no. 3 (Table 1 ) three histologically similar areas have been isolated by microdissection for further DNA isolation and array CGH analysis. The isolated DNA was amplified by whole genome amplification using the GenomePlex Complete Whole Genome Amplification Kit (Sigma, Taufkirchen, Germany) according to the manufacturer's instructions before array CGH. We exemplarily studied the genetic heterogeneity in PTC, with regard to copy number alterations, by comparing the array CGH profiles of the microdissected areas with that obtained from the whole tumour.
Array CGH
To detect small imbalances beyond the spatial resolution of chromosomal CGH, we performed array CGH analyses of PTCs from 33 patients (Table 1) . BAC array slides (1 Mb) containing approximately 3400 BAC clones covering the whole human genome in 1-Mb distances (Fiegler et al., 2003) were spotted in duplicates onto amino-reactive slides (CodeLink, GE Healthcare, Buckinghamshire, England).
To ensure that the extracted DNA was of required quality for use in array CGH experiments, a gene-specific multiplex PCR was used (van Beers et al., 2006) . Only cases with amplification products larger or equal than 300 bp were designated to be of sufficient quality for array CGH analysis. For each experiment, 450 ng of either female or male reference DNA (Promega, Mannheim, Germany) and 450 ng tumour DNA were labelled with Cy3-dCTP and Cy5-dCTP (Perkin Elmer, Shelton, USA), respectively, in an overnight incubation at 37 1C using the BioPrime-Labelling Kit (Invitrogen, Karlsruhe, Germany). Test and reference DNAs were co-hybridized for 40 h with 135 mg cot-1 DNA (Invitrogen), washed and dried in an automated hybridization station (HS400, Tecan, Crailsheim, Germany). Hybridizations have been performed 'sex-mismatched', which means that male tumour DNA was hybridized versus female reference DNA and vice versa. The slides were scanned (GenePix Personal 4100A, Axon Laboratories, Molecular Devices Corp, Chicago, IL, USA) and intensity ratios measured with an arrayanalysis software (GenePix Pro 6.0, Axon Laboratories). Further data analysis was performed using the web-based array CGH evaluation platform CAPweb (Hupe et al., 2004; Neuvial et al., 2006) , which was installed on a local via an intranet accessible web server. After import of raw data into CAPweb, the normalization procedure using the R-package MANOR was performed using default parameters (exclusion of data points with a replicate deviation of >0.1 and/or a foreground to background signal ratio of o3). Segmentation of the data set using the R-package GLAD, which is connected to CAPweb was performed using default parameters with exception of the parameters GLAD.deltaN (set to 1 times the standard deviation (s.d.) of smoothed Log2 ratios of each data set) and GLAD. forceGL1/2 (set to 1.2 times s.d. of smoothed Log2 ratios of each data set). Data were exported to the array data visualization tool VAMP (La and analysed for genomic copy number alterations. Common regions of alterations of the analysed cases were determined using the minimal-alteration algorithm (Rouveirol et al., 2006) , which is integrated into the VAMP software. Regions representing copy number alterations were further analysed using the web-accessible database Ensembl (http://www.ensembl.org) on the basis of NCBI build 36.
FISH analysis using BAC clones
We selected BAC clones from the 1 Mb BAC array, representing amplified or deleted regions (1p22, 1q31, 3p12, 6q21, 7p22, 12q24, 13q21, 19q13, 20q13) and labelled BAC-DNA with biotin or digoxigenin by nick translation according to the standard protocols. Hybridization of BAC clones to paraffin-embedded tissue sections of a representative PTC case carrying the respective alteration and detection of fluorescent signals were performed as described previously (Unger et al., 2004) .
BRAF T1796 mutation analysis
The frequency of the BRAF T1796 mutation was investigated by PCR as published previously (Powell et al., 2005) . Briefly, PCR was used to amplify a 224 bp sequence in exon 15 of the BRAF gene using forward primer 5 0 -TCATAATGCTTGC TCTGATAGGA-3 0 and reverse primer 5 0 -GGCCAAAAATT TAATCAGTGGA-3 0 . Reactions contained 2.5 mM MgCl 2 , 0.2 mM dNTPs, 1 mM of each primer and 0.5 U of AmpliTaq Gold polymerase (Applied Biosystems, Warrington, UK) in a total volume of 30 ml. Five microliters of each PCR product were run on a 2% agarose gel to assess size and amount of amplification products. The 224 bp amplimer was further cut with TspR1. In the mutated sequence, one TspR1 site is lost leading to different digestion products. Five microliters of each PCR product were digested, and restriction fragments were resolved on polyacrylamide gels with silver staining.
Statistical analysis
Distinct genome-wide patterns of chromosomal imbalances were explored using (i) unsupervised HCA on the basis of correlation coefficient distance and average linkage method; (ii) principal component analysis. Fisher's exact test was then used for association of groups from cluster analysis with those given by patient characteristics (age status, RET/PTC status), and for statistical two-group comparisons of amplified and deleted regions. Every BAC clone within altered regions was tested. If the alteration occurred at least five times within a tumour group, P-values have been adjusted using the Benjamini-Hochberg FDR-controlling procedure to obtain reliable significance levels with the high number of tests performed. Results of statistical tests were assigned to chromosomal segments for a clear presentation of data (shown in Table 2 ).
Abbreviations BAC, bacterial artificial chromosome; CGH, comparative genomic hybridization; FISH, fluorescence in situ hybridization; PTC, papillary thyroid carcinoma.
